[11C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer |
| |
Authors: | Alex J Poot Berend van der Wildt Marijke Stigter-van Walsum Marissa Rongen Robert C Schuit N Harry Hendrikse Jonas Eriksson Guus AMS van Dongen Albert D Windhorst |
| |
Institution: | 1. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands;2. Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, the Netherlands;3. Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, the Netherlands |
| |
Abstract: | IntroductionTyrosine kinase inhibitors (TKIs) like sorafenib are important anticancer therapeutics with thus far limited treatment response rates in cancer patients. Positron emission tomography (PET) could provide the means for selection of patients who might benefit from TKI treatment, if suitable PET tracers would be available. The aim of this study was to radiolabel sorafenib (1) with carbon-11 and to evaluate its potential as TKI-PET tracer in vivo.MethodsSynthetic methods were developed in which sorafenib was labeled at two different positions, followed by a metabolite analysis in rats and a PET imaging study in tumor-bearing mice.Resultsmethyl-11C]-1 and urea-11C]-1 were synthesized in yields of 59% and 53%, respectively, with a purity of > 99%. The identity of the products was confirmed by coinjection on HPLC with reference sorafenib. In an in vivo metabolite analysis 11C]sorafenib proved to be stable. The percentage of intact product in blood–plasma after 45 min was 90% for methyl-11C]-1 and 96% for urea-11C]-1, respectively. Due to the more reliable synthesis, further research regarding PET imaging was performed with methyl-11C]-1 in nude mice bearing FaDu (head and neck cancer), MDA-MB-231 (breast cancer) or RXF393 (renal cancer) xenografts. Highest tracer accumulation at a level of 2.52 ± 0.33 %ID/g was observed in RXF393, a xenograft line extensively expressing the sorafenib target antigen Raf-1 as assessed by immunohistochemistry.ConclusionIn conclusion, we have synthesized 11C]sorafenib as PET tracer, which is stable in vivo and has the capability to be used as PET tracer for imaging in tumor-bearing mice. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|